drugset / Trial / NCT03732274
Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This is an open -label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination with durvalumab in patients advanced NSCLC who progressed following platinum-based chemotherapy.
Timeline
- Start
- 2019-02-11
- Primary completion
- 2024-05-17
- Completion
- 2024-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vactosertib | Small molecule | 100 mg | Oral |
| Subject | Vactosertib | Small molecule | 200 mg | Oral |
| Background | Durvalumab | Monoclonal antibody | 1500 mg | — |